Bright Minds Biosciences Inc. (DRUG)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Ian McDonald | Co-Founder, CEO, President & Director | -- | -- | 1988 |
| Mr. Ryan E. S. K. Cheung B.Com., CA, CPA | Chief Financial Officer | 86.17k | -- | 1978 |
| Dr. Jan Torleif Pedersen M.Sc., Ph.D. | Chief Science Officer & Director | 174.7k | -- | 1965 |
| Mr. Alex Vasilkevich | COO & Senior Scientific Officer | -- | -- | -- |
| Dr. Emer Leahy M.B.A., Ph.D. | Consultant | -- | -- | 1967 |
| Dr. Stephen D. Collins M.D., Ph.D. | Chief Medical Officer | -- | -- | 1953 |
Bright Minds Biosciences Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
Description
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatry and neurology indications. Bright Minds Biosciences Inc. has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was founded in 2017 and is headquartered in New York, New York.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
February 12, 2025 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission